JAK1选择性抑制剂治疗类风湿关节炎的早期研究
本文综述了选择性JAK1抑制剂upadacitinib、filgotinib和itacitinib在类风湿关节炎早期(I-II期)研究中的表现。Upadacitinib和filgotinib的早期研究为难治性RA人群提供了疗效和安全性证据,并支持通过平衡获益-风险选择合适剂量以推进III期试验;Itacitinib在II期RA试验中亦显示良好疗效和安全性,但主要开发方向为血液和肿瘤疾病。
要点
- Upadacitinib和filgotinib的早期研究支持其在难治性RA中的疗效与安全性。
- 早期剂量选择基于平衡最佳获益-风险特征,为后续III期试验提供依据。
- Itacitinib在RA的II期试验中显示良好疗效和安全性,但主要开发用于血液和肿瘤疾病。
核心结论
- 选择性JAK1抑制剂upadacitinib和filgotinib的早期研究为难治性RA提供了疗效和安全性证据,并支持剂量选择。
- Itacitinib在RA的II期试验中显示良好疗效和安全性,但主要开发用于血液和肿瘤疾病。
研究设计与样本
- 本文为综述,汇总了upadacitinib、filgotinib和itacitinib在RA中的早期(I-II期)研究。
主要发现
- Upadacitinib和filgotinib的早期研究在难治性RA人群中提供了疗效和安全性证据。
- 早期研究通过平衡最佳获益-风险特征支持选择合适剂量以进一步开展III期试验。
- Itacitinib在RA的II期试验中显示良好疗效和安全性。
临床怎么用
- 选择性JAK1抑制剂的早期研究结果支持在难治性RA中评估其疗效与安全性,并为剂量选择提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were developed with the aim of improving the safety-efficacy profile and to further increase drug maintenance. With this proposal, early phase trials of selective JAK1 inhibitors, namely upadacitinib, filgotinib and itacitinib, were initiated in recent years to identify the efficacy and adverse effects of these agents and to define their potential role in treatment of inflammatory and autoimmune diseases. Early phase (Phase I-II) studies of upadacitinib and filgotinib provided evidence for efficacy and safety of the selective JAK1 inhibitors in refractory populations of RA patients and allowed informed selection of the appropriate dose by balancing the optimal benefit-risk profile for further evaluation in the later successfully performed Phase III trials. Although itacitinib also demonstrated a good efficacy and safety in a Phase II trial in RA patients, it is mainly in development for haematologic and oncologic conditions.
引用
- Avci AB, Feist E, Burmester GR, et al. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 33950228. doi:10.1093/rheumatology/keaa893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。